Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Mar;36(3):558–565. doi: 10.1128/aac.36.3.558

In vitro activity of sparfloxacin compared with those of five other quinolones.

E Cantón 1, J Pemán 1, M T Jimenez 1, M S Ramón 1, M Gobernado 1
PMCID: PMC190557  PMID: 1320362

Abstract

The in vitro activity of sparfloxacin, a new difluorinated quinolone, was evaluated against 857 gram-positive and gram-negative clinical isolates and compared with those of ciprofloxacin, norfloxacin, ofloxacin, fleroxacin, and lomefloxacin. The MIC of sparfloxacin for 90% of the members of the family Enterobacteriaceae tested was 0.5 microgram/ml (range, 0.06 to 4.0 micrograms/ml); only for members of the genera Serratia, Citrobacter, and Providencia were MICs above 1 microgram/ml. Some 90% of Pseudomonas aeruginosa isolates were inhibited by 8 micrograms of the drug per ml. The MICs for 90% of Staphylococcus spp. and Enterococcus faecalis were 0.12 and 2 micrograms/ml, respectively. All (100%) Streptococcus pneumoniae strains were inhibited by 0.5 microgram/ml. The inoculum size had little effect on either the MIC or the MBC of sparfloxacin. An increase in the magnesium concentration from 1.1 to 8.4 mM increased the MIC between 2 and 10 times, depending on the genus tested. Sparfloxacin was less active at pH 5. The antibacterial activity of sparfloxacin against gram-positive bacteria was generally higher than those of the quinolones with which it was compared; against Streptococcus pneumoniae, sparfloxacin was four- and eightfold more active than ofloxacin and ciprofloxacin, respectively. The activity of sparfloxacin against gram-negative rods was generally comparable to that of ciprofloxacin except against Enterobacter and Acinetobacter spp., Pseudomonas cepacia, Xanthomonas maltophilia, and Alcaligenes and Flavobacterium spp., against which sparfloxacin was the most active quinolone.

Full text

PDF
561

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campoli-Richards D. M., Monk J. P., Price A., Benfield P., Todd P. A., Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373–447. doi: 10.2165/00003495-198835040-00003. [DOI] [PubMed] [Google Scholar]
  2. Chaudhry A. Z., Knapp C. C., Sierra-Madero J., Washington J. A. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother. 1990 Sep;34(9):1843–1845. doi: 10.1128/aac.34.9.1843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
  4. Doebbeling B. N., Pfaller M. A., Bale M. J., Wenzel R. P. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. Eur J Clin Microbiol Infect Dis. 1990 Apr;9(4):298–301. doi: 10.1007/BF01968067. [DOI] [PubMed] [Google Scholar]
  5. Fernandes C. J., Ackerman V. P. In vitro studies of ciprofloxacin and survey of resistance patterns in current isolates. Diagn Microbiol Infect Dis. 1990 Mar-Apr;13(2):79–91. doi: 10.1016/0732-8893(90)90090-i. [DOI] [PubMed] [Google Scholar]
  6. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990 Jun;34(6):1123–1127. doi: 10.1128/aac.34.6.1123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. LESHER G. Y., FROELICH E. J., GRUETT M. D., BAILEY J. H., BRUNDAGE R. P. 1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. J Med Pharm Chem. 1962 Sep;91:1063–1065. doi: 10.1021/jm01240a021. [DOI] [PubMed] [Google Scholar]
  9. Mandell W., Neu H. C. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother. 1986 May;29(5):852–857. doi: 10.1128/aac.29.5.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Nakamura S., Kurobe N., Ohue T., Hashimoto M., Shimizu M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother. 1990 Jan;34(1):89–93. doi: 10.1128/aac.34.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Norrby S. R., Jonsson M. Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative. Antimicrob Agents Chemother. 1988 Aug;32(8):1278–1281. doi: 10.1128/aac.32.8.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rolston K. V., Nguyen H., Messer M., LeBlanc B., Ho D. H., Bodey G. P. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Antimicrob Agents Chemother. 1990 Nov;34(11):2263–2266. doi: 10.1128/aac.34.11.2263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Simor A. E., Fuller S. A., Low D. E. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob Agents Chemother. 1990 Nov;34(11):2283–2286. doi: 10.1128/aac.34.11.2283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Yajko D. M., Sanders C. A., Nassos P. S., Hadley W. K. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Antimicrob Agents Chemother. 1990 Dec;34(12):2442–2444. doi: 10.1128/aac.34.12.2442. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES